|
Measuring potency for gene and cell therapies is not so clear-cut, and some companies have hit roadblocks in their submissions to regulatory agencies as a result. This webinar will look at ways to overcome that hurdle as well as challenges in relation to the "talent shortage" that exists because of the rapid growth of the industry, how collaboration is helping the sector progress, and more.
Dr Sharon Barkatullah Head of Analytical Development - Technology and Process Innovation Cell and Gene Therapy Catapult Dr Barkatullah joined the Cell and Gene Therapy Catapult as Head of Analytical Development in May 2022. She leads a team of analytical scientists who specialise in both cell and gene therapy analytical development. She brings over 20 years of wide-ranging analytics experience gained in cell therapy, large pharma, biotech and medical diagnostics. Within stem cell CMC she led the analytical development of stem cell-derived products into first-in-human trials.
Daniel Gibson Director of Cell and Gene Therapy Services Anthony Nolan Dan is a seasoned strategic leader and change agent with over a decade of experience in process development and clinical delivery. Having demonstrated a commitment to facilitating the delivery of innovative treatments for patients, coupled with a dedication to providing high-quality, innovative solutions within regulatory frameworks. Currently serving as the Director of Cell and Gene Therapy Services at Anthony Nolan, Dan provides strategic leadership, driving innovation and ensuring regulatory compliance while delivering high-quality standards. Ensuring Allo therapies have the foundation to scale when needed. With a passion for driving positive change and a track record of success in their field, Dan brings a wealth of knowledge and passion for making impactful contributions to the healthcare industry and beyond.
Dan Shelly, PhD, MBA Chief Business Development Officer PolTREG Dan was appointed Chief Business Development Officer at PolTREG in February 2024. Previously, he was the VP of Business Development and Alliances at Prescient Therapeutics where he was responsible for advancing a next-generation, modular, and post-infusion controllable CAR-Immune cell therapy platform along with small molecule targeted therapies. Previously, he was Director of Global Business Development and Strategic Partnerships for the global non-profit PATH, where he was the Co-Lead for the COVID-19 task force. He has over 19 years of biopharmaceutical BD licensing and alliance management experience. He is also an adjunct professor in the Masters in Clinical Drug Development program at the University of Cincinnati’s College of Pharmacy.
Piotr Trzonkowski CEO PolTREG As Chief Executive Officer of PolTREG, Piotr Trzonkowski saw to it that the company built up one of the most comprehensive pipelines in cellular therapies for autoiommune diseases, developing both polyclonal and engineered cells. The company has treated more than 100 patients with its cell therapies at its proprietary CGMP facility over the last 17 years. This has provided PolTREG with a wealth of data and unrivalled experience with how autoimmune such as Type-1 Diabetes respond to various treatments. Piotr is a leading expert in the field, and a professor at the University of Gdansk.
Isabel Cameron Reporter BioPharma-Reporter Currently working as a Reporter across Bio-Pharma Reporter and Outsourcing Pharma, Isabel joined William Reed in May 2023 from Retail Gazette. She has extensive experience in digital journalism, writing and editing daily news stories, long-form articles, social media copy and interviewing high-profile industry experts.
|
|
First Name
|
Last Name
|
Email Address
|
Job Seniority
|
Job Title
|
Job Function
|
Company
|
Company Activity
|
Company Employees
|
Phone
|
Country
|
|
Got a burning question about this topic? Send it to us using the box below and we will try to have it answered by our expert panellists. You are also welcome to ask questions on the live day
|
|
This Webinar is a free service provided to you by BioPharma-Reporter. The content of this service is sponsored by the partners named on this page. In order for you to receive this content, the above data is provided to these partners. Additional partners may join at a later stage and the full list of partners will be available on the day you access the webinar. |
|
BioPharma-Reporter may use your contact data to keep you informed of its products and services by email or by phone. You can withdraw your marketing consent at any time by clicking the unsubscribe link in such email or by sending an email to dataprivacy@wrbm.com
More information on our processing can be found in our Privacy Notice. By submitting this form, you acknowledge that you have read and understand our Privacy Notice |
|
|
|
|
|